Reducing excess broad-spectrum antibiotic use in gonorrhea
减少淋病中过量使用广谱抗生素
基本信息
- 批准号:9263889
- 负责人:
- 金额:$ 23.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-04-19 至 2019-03-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAgarAllelesAntibiotic ResistanceAntibiotic TherapyAntibioticsAntimicrobial ResistanceAntimicrobial susceptibilityAzithromycinBiological AssayCaliforniaCefiximeCeftriaxoneCell WallCenters for Disease Control and Prevention (U.S.)Cephalosporin ResistanceCephalosporinsCharacteristicsCiprofloxacinClinicalClinical ManagementCounselingDNA Sequence AlterationDataDetectionDiagnosisDoxycyclineDrug resistanceDrug-resistant Neisseria GonorrhoeaeEcologyEnzymesErythromycinEvolutionFinlandFluoroquinolonesFrequenciesGenesGeneticGonorrheaHealth systemHumanIndividualInfectionInjectableJapanLaboratoriesMacrolide-resistanceMaintenanceManufacturer NameMedicineMethodsMinimum Inhibitory Concentration measurementModernizationMolecularMorbidity - disease rateMosaicismMulti-Drug ResistanceMutationMycobacterium tuberculosisNeisseria gonorrhoeaeNucleic Acid Amplification TestsOralOutcome StudyPatientsPenicillinsPerformancePharmaceutical PreparationsPhenotypePlayPolymerase Chain ReactionPredispositionProtocols documentationProviderPublic HealthRecommendationRegulationResearchResistanceRisk ReductionRoleSexually Transmitted DiseasesSouth AfricanSpecimenStaphylococcus aureusStreptococcal InfectionsSuperbugTechniquesTestingTetracyclinesTimeTreatment FailureUnited Statesantimicrobial drugbasecondomsdisorder preventiondrug developmentdrug-resistant gonorrheaefflux pumpexperiencemen who have sex with menmolecular markermortalitynovelnovel strategiespersonalized approachprimary outcomeprogramspublic health relevanceresponsescreeningsecondary outcomesurveillance datavigilance
项目摘要
DESCRIPTION (provided by applicant): The proposed research represents a novel approach to controlling the spread of drug-resistant Neisseria gonorrhoeae through the use of a multiplex real-time polymerase chain reaction (PCR) assay to determine antimicrobial susceptibility of an individual infection and reduce the unnecessary use of broad spectrum antibiotics. Over the past 75 years, gonorrhea has become increasingly resistant to antimicrobial therapy. The continued emergence of drug-resistance in gonorrhea has many experts stating that gonorrhea might become an untreatable "superbug". Yet, the response to this serious public health problem continues to rely on clinical vigilance for treatment failure, partner treatment, maintenance of culture-based surveillance, risk-reduction counseling, condom use, repeat screening and calls for novel antimicrobial drug development. The use of molecular assays for antimicrobial susceptibility determination has been successfully used to treat M. tuberculosis and Staphylococcus aureus infections, but not yet with gonorrhea. The use of real-time PCR to determine antimicrobial susceptibility could be a "game changer" that alters the course of sexually transmitted disease medicine and leads to a critical reduction in gonorrhea drug-resistance. There are three specific aims to our proposal: 1) We will verify a real-time multiplex PCR assay in the detection of ciprofloxacin- and cefixime-susceptible NG infections in accordance with CLIA regulations. 2) We will develop a molecular antimicrobial susceptibility detection program for clinical use at a large health system and reference laboratory. 3) We will determine the impact of providing clinicians with molecular antimicrobial susceptibility results on
their prescribed treatment of patients diagnosed with NG. The primary outcome of this study is the difference in the proportion of NG cases treated with injectable ceftriaxone before and after the provision of susceptibility results. Based on prior research, we hypothesize an 80% relative reduction in injectable extended-spectrum cephalosporin use from 95% to 19%. Secondary outcomes will explore the association of ciprofloxacin and cefixime use with both provider and case-patient characteristics. Overall, the study results will potentially transform the management of gonorrhea and impact the frequency of drug-resistant gonorrhea.
描述(由申请人提供):拟定研究代表了一种通过使用多重实时聚合酶链反应(PCR)测定来确定个体感染的抗菌药物敏感性并减少广谱抗生素的不必要使用来控制耐药淋病奈瑟菌传播的新方法。在过去的75年里,淋病对抗菌治疗的耐药性越来越强。淋病耐药性的持续出现使许多专家指出淋病可能成为一种无法治愈的“超级细菌”。然而,对这一严重公共卫生问题的应对仍然依赖于对治疗失败的临床警惕、伴侣治疗、维持基于培养的监测、降低风险咨询、使用避孕套、重复筛查和呼吁开发新型抗菌药物。利用分子生物学方法测定抗生素敏感性已成功地用于治疗M。结核病和金黄色葡萄球菌感染,但还没有淋病。使用实时PCR来确定抗菌药物的敏感性可能是一个“游戏规则改变者”,改变了性传播疾病的药物治疗过程,并导致淋病耐药性的严重减少。我们的提案有三个具体目标:1)我们将根据CLIA法规验证实时多重PCR检测环丙沙星和头孢肟敏感NG感染的方法。2)我们将开发一个分子抗菌药物敏感性检测程序,供大型卫生系统和参考实验室临床使用。3)我们将确定向临床医生提供分子抗菌药物敏感性结果对
他们对诊断为NG的患者的处方治疗。本研究的主要结局是提供药敏结果前后接受注射用头孢曲松治疗的NG病例比例的差异。基于先前的研究,我们假设注射用超广谱头孢菌素的使用从95%相对减少80%到19%。次要结果将探讨环丙沙星和头孢克肟的使用与供应商和病例-患者特征的关联。总的来说,研究结果可能会改变淋病的管理,并影响耐药淋病的频率。
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Real-Time PCR Targeting the penA Mosaic XXXIV Type for Prediction of Extended-Spectrum-Cephalosporin Susceptibility in Clinical Neisseria gonorrhoeae Isolates.
针对 penA Mosaic XXXIV 型的实时 PCR 预测临床淋病奈瑟菌分离株中的超广谱头孢菌素敏感性。
- DOI:10.1128/aac.01339-17
- 发表时间:2017
- 期刊:
- 影响因子:4.9
- 作者:Wong,LK;Hemarajata,P;Soge,OO;Humphries,RM;Klausner,JD
- 通讯作者:Klausner,JD
A multisite implementation of a real-time polymerase chain reaction assay to predict ciprofloxacin susceptibility in Neisseria gonorrhoeae.
多位点实施实时聚合酶链式反应测定,以预测淋病奈瑟菌对环丙沙星的敏感性。
- DOI:10.1016/j.diagmicrobio.2018.12.018
- 发表时间:2019
- 期刊:
- 影响因子:2.9
- 作者:Ellis,Olivia;Hemarajata,Peera;Shahkolahi,Akbar;Masinde,Godfred;Buchs,Kerry;Humphries,RomneyM;Klausner,JeffreyD
- 通讯作者:Klausner,JeffreyD
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jeffrey David Klausner其他文献
Jeffrey David Klausner的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jeffrey David Klausner', 18)}}的其他基金
Pilot study of linezolid for early syphilis treatment
利奈唑胺治疗早期梅毒的初步研究
- 批准号:
10575509 - 财政年份:2022
- 资助金额:
$ 23.1万 - 项目类别:
Evaluating STI screening and antimicrobial resistance in Neisseria gonorrhoeae among PrEP users in Vietnam
评估越南 PrEP 使用者中性传播感染筛查和淋病奈瑟菌耐药性
- 批准号:
10389089 - 财政年份:2021
- 资助金额:
$ 23.1万 - 项目类别:
Evaluating STI screening and antimicrobial resistance in Neisseria gonorrhoeae among PrEP users in Vietnam
评估越南 PrEP 使用者中性传播感染筛查和淋病奈瑟菌耐药性
- 批准号:
10343849 - 财政年份:2021
- 资助金额:
$ 23.1万 - 项目类别:
Clinical Trial Comparing the Effectiveness of Cefixime Versus Penicillin G for Treatment of Early Syphilis
比较头孢克肟与青霉素 G 治疗早期梅毒疗效的临床试验
- 批准号:
10417271 - 财政年份:2020
- 资助金额:
$ 23.1万 - 项目类别:
Clinical Study of STI Screening to Prevent Adverse Birth and Newborn Outcomes
性传播感染筛查预防不良分娩和新生儿结局的临床研究
- 批准号:
10555240 - 财政年份:2020
- 资助金额:
$ 23.1万 - 项目类别:
Clinical Study of STI Screening to Prevent Adverse Birth and Newborn Outcomes
性传播感染筛查预防不良分娩和新生儿结局的临床研究
- 批准号:
10385627 - 财政年份:2020
- 资助金额:
$ 23.1万 - 项目类别:
Clinical trial comparing the effectiveness of cefixime versus penicillin G for treatment of early syphilis
比较头孢克肟与青霉素 G 治疗早期梅毒有效性的临床试验
- 批准号:
10079905 - 财政年份:2020
- 资助金额:
$ 23.1万 - 项目类别:
Clinical Study of STI Screening to Prevent Adverse Birth and Newborn Outcomes
性传播感染筛查预防不良分娩和新生儿结局的临床研究
- 批准号:
10322132 - 财政年份:2020
- 资助金额:
$ 23.1万 - 项目类别:
Clinical Trial Comparing the Effectiveness of Cefixime Versus Penicillin G for Treatment of Early Syphilis
比较头孢克肟与青霉素 G 治疗早期梅毒疗效的临床试验
- 批准号:
10652990 - 财政年份:2020
- 资助金额:
$ 23.1万 - 项目类别:
Clinical Trial Comparing the Effectiveness of Cefixime Versus Penicillin G for Treatment of Early Syphilis
比较头孢克肟与青霉素 G 治疗早期梅毒疗效的临床试验
- 批准号:
10392825 - 财政年份:2020
- 资助金额:
$ 23.1万 - 项目类别:
相似国自然基金
Cd(II)在NH2-Agar/PSS双网络水凝胶上的吸附行为及资源化工艺研究
- 批准号:51708204
- 批准年份:2017
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
相似海外基金
An ethnographic study on the utilization and allocation of sea resources among agar divers in Japan, Taiwan and Korea
日本、台湾、韩国琼脂潜水者海洋资源利用与配置的人种学研究
- 批准号:
19K13467 - 财政年份:2019
- 资助金额:
$ 23.1万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Edible optical systems made of agar
由琼脂制成的可食用光学系统
- 批准号:
18K19799 - 财政年份:2018
- 资助金额:
$ 23.1万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Agar-based gel-electrolytes for corrosion diagnostic
用于腐蚀诊断的琼脂基凝胶电解质
- 批准号:
330472124 - 财政年份:2017
- 资助金额:
$ 23.1万 - 项目类别:
Research Grants
Micro-Patterning of Agar Surface for Cultivation Control of Microbes
用于微生物培养控制的琼脂表面微图案化
- 批准号:
15K14703 - 财政年份:2015
- 资助金额:
$ 23.1万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Elucidation of the mechanism that heterotrophic bacteria induce the growth of the cyanobacterial strain on agar media
阐明异养细菌诱导蓝藻菌株在琼脂培养基上生长的机制
- 批准号:
26650166 - 财政年份:2014
- 资助金额:
$ 23.1万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
The Production of Japanese Agar and Gelatin in Edo Period
江户时代日本琼脂和明胶的生产
- 批准号:
21520663 - 财政年份:2009
- 资助金额:
$ 23.1万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Organization of Novel Marine Bacterial Structures Involved in the Degradation of Agar
参与琼脂降解的新型海洋细菌结构的组织
- 批准号:
0109869 - 财政年份:2001
- 资助金额:
$ 23.1万 - 项目类别:
Continuing Grant
Swallowing Characteristics of Bolus of Agar Gels on the Swallowing Process
琼脂凝胶丸剂对吞咽过程的吞咽特性
- 批准号:
09680040 - 财政年份:1997
- 资助金额:
$ 23.1万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
HIGH FREQUENCY FLUX CONTROL OF MAGNETIC AGAR USING PLANT MAGNETIC MATERIAL AND ITS APPLICATIONS
植物磁性材料对磁性琼脂的高频通量控制及其应用
- 批准号:
08555095 - 财政年份:1996
- 资助金额:
$ 23.1万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Raum-Zeit-Strukturen von Ca2+-Signalen in einem SR-Vesikel-Agar-System; Experimente und Modellierung
SR囊泡琼脂系统中Ca2信号的时空结构;
- 批准号:
5194244 - 财政年份:1995
- 资助金额:
$ 23.1万 - 项目类别:
Research Grants